Health-Related Quality of Life in Japanese Patients with Prostate Cancer Using EQ-5D-5L and FACT-P: Comparisons According to Treatment Type

As novel therapies such as hormone treatment for castration-resistant prostate cancer are added to the reimbursement list of public healthcare insurance, treatment of this disease in Japan become more complex. Under these circumstances, health technology assessment -especially cost-utility analysis- is important in the decision-making process for prostate cancer treatment. This study measured and compared the health-related quality of life...